FBXO22 and breast cancer: Similalry, KDM4B degradation is mediated by FBXO22 in breast cancer cells, resulting in regulation of selective estrogen receptor modulators (SERMs) activity, leading to modulation of tamoxifen resistance in ER-positive breast cancer cells33.